Trastuzumab Deruxtecan Receives FDA Approval for Metastatic HER2+ Breast Cancer
May 5th 2022, 1:25pm
Findings from the phase 3 DESTINY-Breast03 trial have led to the FDA approval of fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.